MediPharm Labs Corp.
LABS.TO
TSX
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | 39.81% | 36.96% | 11.98% | -17.31% | 50.43% |
| Total Depreciation and Amortization | -23.95% | -17.43% | 3.71% | 61.74% | 32.48% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -264.18% | 186.93% | 121.21% | 174.06% | -55.70% |
| Change in Net Operating Assets | -74.39% | -32.97% | 63.35% | -9.62% | -21.03% |
| Cash from Operations | -170.35% | 79.86% | 79.06% | 49.82% | 975.12% |
| Capital Expenditure | 64.11% | 87.51% | 18.04% | 15.68% | 61.56% |
| Sale of Property, Plant, and Equipment | -100.00% | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -29.51% |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -100.99% | -101.98% | -103.64% | 2,204.86% | -24.66% |
| Total Debt Issued | -- | -- | -29.80% | -- | -- |
| Total Debt Repaid | 13.81% | -490.72% | 81.27% | 35.18% | 27.32% |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -47.33% | -77.53% | -89.42% | 140.28% | 7.91% |
| Cash from Financing | 1.58% | -630.87% | -38.36% | 92.79% | 39.76% |
| Foreign Exchange rate Adjustments | 91.04% | -81.56% | -75.83% | -- | -13.85% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -127.08% | -59.09% | 83.03% | 73.51% | 7.00% |